Kwangdong Phar (009290) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kwangdong Phar (009290) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩26.03 Billion ≈ $17.64 Million USD) by net assets (₩632.20 Billion ≈ $428.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kwangdong Phar - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Kwangdong Phar's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 009290 total debt and obligations for a breakdown of total debt and financial obligations.
Kwangdong Phar Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kwangdong Phar ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
0.119x |
|
Argo Pantes Tbk
JK:ARGO
|
0.149x |
|
Grupo Minsa S.A.B. de C.V
MX:MINSAB
|
0.009x |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
0.008x |
|
Niu Technologies
F:0O9
|
N/A |
|
Tonghua Grape Wine Co Ltd
SHG:600365
|
-0.411x |
|
PERPETUAL EQU. INV.
F:P82
|
N/A |
|
Great China Metal Industry Co Ltd
TW:9905
|
0.023x |
Annual Cash Flow Conversion Efficiency for Kwangdong Phar (2011–2024)
The table below shows the annual cash flow conversion efficiency of Kwangdong Phar from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 009290 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩618.27 Billion ≈ $418.99 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.020x | +1.46% |
| 2023-12-31 | ₩588.05 Billion ≈ $398.51 Million |
₩-11.73 Billion ≈ $-7.95 Million |
-0.020x | -117.37% |
| 2022-12-31 | ₩547.05 Billion ≈ $370.73 Million |
₩62.82 Billion ≈ $42.57 Million |
0.115x | +10.21% |
| 2021-12-31 | ₩527.24 Billion ≈ $357.31 Million |
₩54.94 Billion ≈ $37.23 Million |
0.104x | +129.22% |
| 2020-12-31 | ₩502.18 Billion ≈ $340.32 Million |
₩22.83 Billion ≈ $15.47 Million |
0.045x | -30.54% |
| 2019-12-31 | ₩447.46 Billion ≈ $303.24 Million |
₩29.29 Billion ≈ $19.85 Million |
0.065x | -46.89% |
| 2018-12-31 | ₩430.84 Billion ≈ $291.97 Million |
₩53.10 Billion ≈ $35.98 Million |
0.123x | +118.65% |
| 2017-12-31 | ₩416.30 Billion ≈ $282.12 Million |
₩23.46 Billion ≈ $15.90 Million |
0.056x | -21.78% |
| 2016-12-31 | ₩399.68 Billion ≈ $270.86 Million |
₩28.80 Billion ≈ $19.52 Million |
0.072x | -33.84% |
| 2015-12-31 | ₩377.73 Billion ≈ $255.98 Million |
₩41.14 Billion ≈ $27.88 Million |
0.109x | +4.55% |
| 2014-12-31 | ₩314.40 Billion ≈ $213.06 Million |
₩32.75 Billion ≈ $22.19 Million |
0.104x | -11.92% |
| 2013-12-31 | ₩290.82 Billion ≈ $197.09 Million |
₩34.39 Billion ≈ $23.31 Million |
0.118x | +33.16% |
| 2012-12-31 | ₩267.27 Billion ≈ $181.13 Million |
₩23.74 Billion ≈ $16.09 Million |
0.089x | -19.93% |
| 2011-12-31 | ₩249.52 Billion ≈ $169.09 Million |
₩27.68 Billion ≈ $18.76 Million |
0.111x | -- |
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more